- Home
- EVC vs FDMT Comparison
EVC vs FDMT Comparison
Compare EVC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- FDMT
- Stock Information
- Founded
- EVC 1996
- FDMT 2013
- Country
- EVC United States
- FDMT United States
- Employees
- EVC N/A
- FDMT N/A
- Industry
- EVC Broadcasting
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- FDMT Health Care
- Exchange
- EVC Nasdaq
- FDMT Nasdaq
- Market Cap
- EVC 188.3M
- FDMT 192.2M
- IPO Year
- EVC 2000
- FDMT 2020
- Fundamental
- Price
- EVC $2.47
- FDMT $7.26
- Analyst Decision
- EVC
- FDMT Buy
- Analyst Count
- EVC 0
- FDMT 9
- Target Price
- EVC N/A
- FDMT $30.63
- AVG Volume (30 Days)
- EVC 184.3K
- FDMT 2.4M
- Earning Date
- EVC 08-05-2025
- FDMT 08-11-2025
- Dividend Yield
- EVC 8.02%
- FDMT N/A
- EPS Growth
- EVC N/A
- FDMT N/A
- EPS
- EVC N/A
- FDMT N/A
- Revenue
- EVC $396,704,000.00
- FDMT $33,000.00
- Revenue This Year
- EVC $64.06
- FDMT $11,586.49
- Revenue Next Year
- EVC N/A
- FDMT N/A
- P/E Ratio
- EVC N/A
- FDMT N/A
- Revenue Growth
- EVC 25.34
- FDMT N/A
- 52 Week Low
- EVC $1.58
- FDMT $2.24
- 52 Week High
- EVC $2.73
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- EVC 53.83
- FDMT 71.22
- Support Level
- EVC $2.36
- FDMT $5.33
- Resistance Level
- EVC $2.52
- FDMT $5.94
- Average True Range (ATR)
- EVC 0.12
- FDMT 0.65
- MACD
- EVC 0.02
- FDMT 0.18
- Stochastic Oscillator
- EVC 61.32
- FDMT 91.71
About EVC Entravision Communications Corporation
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.